Vancomycin-resistant enterococci (VRE) are Gram-positive bacteria that are resistant to vancomycin. Infections caused by VRE are associated with adverse outcomes such as extended length of hospital stay, increased cost, and high mortality rate. Clinical and surveillance VRE isolates have been reported from Saudi Arabia. In this review, prevalence, characteristics, risk factors, resistance, and virulence of VRE isolates associated with infection and colonization in Saudi Arabia are described.
Get full access to this article
View all access options for this article.
References
1.
MurrayB.1990. The life and times of the Enterococcus. Clin. Microbiol. Rev. 3:46–65.
2.
LebretonF., WillemsR.J.L., and GilmoreM.S.. 2014. Enterococcus diversity, origins in nature, and gut colonization. In GilmoreM.S., ClewellD.B., IkeY., and ShankarN. (eds.), Enterococci: from commensals to leading causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston, MA, pp. 5–63.
3.
MendesR.E., CastanheiraM., FarrellD.J., FlammR.K., SaderH.S., and JonesR.N.. 2016. Longitudinal (2001–2014) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–2013) analysis of oritavancin in vitro potency. J. Antimicrob. Chemother. 71:3453–3458.
4.
Evans PattersonJ.E., SweeneyA.H., SimmsM., CarleyN., MangiR., SabettaJ., and LyonsR.W.. 1995. An analysis of 110 serious enterococcal infections epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore), 74:191–200.
5.
Dutka-MalenS., BlaimontB., WautersG., and CourvalinP.. 1994. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob. Agents Chemother. 38:1675–1677.
6.
NashmiA., and MemishZ.A.. 2007. Infective endocarditis at a tertiary care centre in Saudi Arabia: review of 47 cases over 10 years. East. Mediterr. Health J. 13:64–71.
7.
Al-OtaibiF.E., KambalA.M., and BaabbadR.A.. 2004. Enterococcal bacteremia in a teaching hospital in the Central region of Saudi Arabia. Saudi Med. J. 25:21–25.
8.
Al-TawfiqJ.A., and AbedM.S.. 2009. Prevalence and antimicrobial resistance of health care associated bloodstream infections at a general hospital in Saudi Arabia. Saudi Med. J. 30:1213–1218.
9.
HollenbeckB.L., and RiceL.B.. 2012. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence, 3:421–569.
10.
MunitaJ.M., BayerA.S., and AriasC.A.. 2015. Evolving resistance among gram-positive pathogens. Clin. Infect. Dis. 61:S48–S57.
11.
SavaI.G., HeikensE., and HuebnerJ.. 2010. Pathogenesis and immunity in enterococcal infections. 2010. Clin. Microbiol. Infect. 16:533–540.
12.
DonabedianS.M., PerriM.B., AbdujamilovaN., GordoncilloM.J., NaqviA., ReyesK.C., ZervosM.J., and BartlettP.. 2010. Characterization of vancomycin-resistant Enterococcus faecium isolated from swine in three Michigan counties. J. Clin. Microbiol. 48:4156–4160.
13.
SakkaV., TsiodrasS., GalaniL., AntoniadouA., SouliM., GalaniI., PantelakiM., SiafakasN., ZervaL., and GiamarellouH.. 2008. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin. Microbiol. Infect. 14:14–21.
14.
LaiM.H., and KirschD.R.. 1996. Induction signals for vancomycin resistance encoded by the vanA gene cluster in Enterococcus faecium. Antimicrob. Agents Chemother. 40:1645–1648.
15.
VergisE.N., HaydenM.K., ChowJ.W., SnydmanD.R., ZervosM.J., LindenP.K., WagenerM.M., SchmittB., and MuderR.R.. 2001. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann. Intern. Med. 135:484–492.
16.
CheahA.L., SpelmanT., LiewD., PeelT., HowdenB.P., SpelmanD., GraysonM.L., NationR.L., and KongD.C.. 2013. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin. Microbiol. Infect. 19:E181–E189.
17.
QadriS.M., QunibiW.Y., Al-BallaaS.R., KadhiY., and BurdetteJ.M.. 1993. Vancomycin resistant Enterococcus: a case report and review of literature. Ann. Saudi Med. 13:289–293.
18.
KhanM.A., van der WalM., FarrellD.J., CossinsL., van BelkumA., AlaidanA., and HaysJ.P.. 2008. Analysis of VanA vancomycin-resistant Enterococcus faecium isolates from Saudi Arabian hospitals reveals the presence of clonal cluster 17 and two new Tn1546 lineage types. J. Antimicrob. Chemother. 62:279–283.
QadriS.M., EllisM.E., Al-RabiahF., ErnstP., and IngemanssonS.. 1996. High-level, multiresistant enterococci associated with systemic disease: a report of two cases. Ann. Saudi Med. 16:682–685.
21.
SirkhaziM., SarriffA., AzizN.A., AlmanaF., ArafatO., and ShormanM.. 2014. Bacterial spectrum, isolation sites and susceptibility patterns of pathogens in adult febrile neutropenic cancer patients at a specialist hospital in Saudi Arabia. World J. Oncol. 5:196–203.
22.
Al-AhdalM.N., AbozaidS.M., Al-ShammaryH.F., BoholM.F., Al-ThawadiS.I., Al-JaberiA.A., SenokA.C., ShiblA.M., and Al-QahtaniA.A.. 2012. Characterization of Enterococcus faecium isolates and first report of vanB phenotype-vanA genotype incongruence in the Middle East. Eur. J. Clin. Microbiol. Infect. Dis. 31:3223–3229.
23.
AlotaibiF.E., and BukhariE.E.. 2017. Emergence of vancomycin-resistant enterococci at a teaching hospital, Saudi Arabia. Chin. Med. J. (Engl). 130:340–346.
24.
HassanH., and ShormanM.. 2011. Evaluation of the BD GeneOhm MRSA and VanR assays as a rapid screening tool for detection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in a tertiary hospital in Saudi Arabia. Int. J. Microbiol. 2011:861514.
25.
AsgharA.H.2011. Frequency and antibiotic susceptibility of gram-positive bacteria in Makkah hospitals. Ann. Saudi Med. 31:462–468.
26.
SomilyA.M., Al-MohizeaM.M., AbsarM.M., FataniA.J., RidhaA.M., Al-AhdalM.N., SenokA.C., and Al-QahtaniA.A.. 2016. Molecular epidemiology of vancomycin resistant enterococci in a tertiary care hospital in Saudi Arabia. Microb. Pathog. 97:79–83.
27.
ShiblA.M., MemishZ.A., KambalA.M., OhalyY.A., IshaqA., SenokA.C., and LivermoreD.M.. 2014. National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia. J. Chemother. 26:13–18.
28.
KhanM.A., ShormanM., Al-TawfiqJ., and HaysJ.P.. 2013. New type lineage-related TnF1546 and a vanA/vanB type vancomycin-resistant Enterococcus faecium isolated from patients in Dammam, Saudi Arabia during 2006–2007. Epidemiol. Infect. 141:1109–1114.
29.
ShormanM., and Al-TawfiqJ.A.. 2013. Risk factors associated with vancomycin-resistant Enterococcus in intensive care unit settings in Saudi Arabia. Interdiscip. Perspect. Infect. Dis. 2013:369674.
30.
QadriS.H., and PostleA.G.. 1996. Vancomycin-resistant enterococci (VRE) as normal flora of the intestine in patients at a tertiary care hospital. Ann. Saudi Med. 16:625–628.
31.
El-AminN.M., and FaidahH.S.. 2011. Vancomycin-resistant Enterococci. Prevalence and risk factors for fecal carriage in patients at tertiary care hospitals. Saudi Med. J. 32:966–967.
32.
Salem-BekhitM., MuharramM., HefniH., MoussaI., and AlanazyF.. 2012. Prevalence and antimicrobial resistance pattern of multidrug-resistant enterococci isolated from clinical specimens. Indian J. Med. Microbiol. 30:44–51.
33.
SimnerP.J., AdamH., BaxterM., MccrackenM., GoldingG., KarlowskyJ.A., NicholK., Lagacé-WiensP., AND GilmourM.W.Canadian Antimicrobial Resistance Alliance (CARA), HobanD.J., and ZhanelG.G.. 2015. Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013). Antimicrob. Agents Chemother. 59:4315–4317.
34.
ZhaoC., SunH., WangH., LiuY., HuB., YuY., SunZ., ChuY., CaoB., LiaoK., LeiJ., HuZ., ZhangL., ZhangX., XuY., WangZ., and ChenM.. 2012. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005–2010). Diagn. Microbiol. Infect. Dis. 73:174–181.
35.
OrsiG.B., and CiorbaV.. 2013. Vancomycin resistant enterococci healthcare associated infections. Ann. Ig. 25:485–492.
36.
BiedenbachD.J., MoetG.J., and JonesR.N.. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagn. Microbiol. Infect. Dis. 50:59–69.
37.
RyanL., O'MahonyE., WrennC., FitzGeraldS., FoxU., BoyleB., SchafferK., WernerG., and KlareI.. 2015. Epidemiology and molecular typing of VRE bloodstream isolates in an Irish tertiary care hospital. J. Antimicrob. Chemother. 70:2718–2724.
38.
WernerG., CoqueT.M., HammerumA.M., HopeR., HryniewiczW., JohnsonA., KlareI., KristinssonK.G., LeclercqR., LesterC.H., LillieM., NovaisC., Olsson-LiljequistB., PeixeL.V., SadowyE., SimonsenG.S., TopJ., Vuopio-VarkilaJ., WillemsR.J., WitteW., and WoodfordN.. 2008. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 13:pii:19046.
39.
BuggT.D., WrightG.D., Dutka-MalenS., ArthurM., CourvalinP., and WalshC.T.. 1991. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry, 30:10408–10415.
AriasC.A., and MurrayB.E.. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat. Rev. Microbiol. 10:266–278.
42.
SantonaA., PagliettiB., Al-QahtaniA.A., BoholM.F., SenokA., DeligiosM., RubinoS., and Al-AhdalM.N.. 2014. Novel type of VanB2 teicoplanin-resistant hospital-associated Enterococcus faecium. Int. J. Antimicrob. Agents, 44:156–159.
43.
FisherK., and PhillipsC.. 2009. The ecology, epidemiology and virulence of Enterococcus. Microbiology, 155:1749–1757.
44.
ChowJ.W., ThalL.A., PerriM.B., VazquezJ.A., DonabedianS.M., ClewellD.B., and ZervosM.J.. 1993. Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 37:2474–2477.
45.
SchlievertP.M., GahrP.J., AssimacopoulosA.P., DingesM.M., StoehrJ.A., HarmalaJ.W., HirtH., and DunnyG.M.. 1998. Aggregation and binding substances enhance pathogenicity in rabbit models of Enterococcus faecalis endocarditis. Infect. Immun. 66:218–223.
46.
JettB.D., JensenH.G., NordquistR.E., and GilmoreM.S.. 1992. Contribution of the pAD1-encoded cytolysin to the severity of experimental Enterococcus faecalis endophthalmitis. Infect. Immun. 60:2445–2452.
47.
ShankarN., LockatellC.V., BaghdayanA.S., DrachenbergC., GilmoreM.S., and JohnsonD.E.. 2001. Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. Infect. Immun. 69:4366–4372.
48.
SinghK.V., QinX., WeinstockG.M., and MurrayB.E.. 1998. Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J. Infect. Dis. 178:1416–1420.
